These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 7461364)

  • 21. [Antihypertensive efficacy and effects on intra and extracellular electrolytes of a canrenoate potassium-butizide combination].
    Costa FV; Borghi C; Mussi A; Ambrosioni E
    Minerva Cardioangiol; 1988 Oct; 36(10):503-7. PubMed ID: 3226562
    [No Abstract]   [Full Text] [Related]  

  • 22. Hyperaldosteronism after heart surgery in children. Part I: Treatment with aldosterone antagonists.
    Haschke F; Wimmer M; Parth K
    Padiatr Padol; 1981; 16(3):317-26. PubMed ID: 7254888
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Canrenoate--a spironolactone metabolite. Acute cardiac effects in digitalized patients.
    Waldorff S; Buch J
    Eur J Cardiol; 1979 Aug; 10(2):143-9. PubMed ID: 477703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical experience in the use of Osyrol 100 and Osyrol for injection (author's transl)].
    Gorbach HC; Bräuninger HJ
    MMW Munch Med Wochenschr; 1975 Sep; 117(37):1483-6. PubMed ID: 810673
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effectiveness of K canrenoate in the treatment of secondary hyperaldosteronism].
    Tartagni F; Pasetti L; Ambrosioni E; Magnani B
    G Clin Med; 1979 Mar; 60(3):196-206. PubMed ID: 520727
    [No Abstract]   [Full Text] [Related]  

  • 26. Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral child A cirrhosis.
    Pozzi M; Grassi G; Ratti L; Favini G; Dell'Oro R; Redaelli E; Calchera I; Boari G; Mancia G
    Am J Gastroenterol; 2005 May; 100(5):1110-6. PubMed ID: 15842586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy of canrenoate potassium in hypertensive cardiopathy. Clinical and echocardiographic evaluation].
    Caporicci D; Achilli L
    Minerva Cardioangiol; 1984 Sep; 32(9):581-7. PubMed ID: 6514202
    [No Abstract]   [Full Text] [Related]  

  • 28. [Effect of potassium canrenoate on serum magnesium levels after extracorporeal circulation].
    Tsuji K; Nawa S; Kino K; Teramoto S; Hayashi K
    Kokyu To Junkan; 1992 Aug; 40(8):813-8. PubMed ID: 1529178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cardiac and selective vascular effects of canrenoate-potassium (aldactone pro injectione) in cardiosurgical patients (author's transl)].
    Piepenbrock S; Hempelmann G; Volkholz E; Oelert H
    Prakt Anaesth; 1977 Oct; 12(5):400-12. PubMed ID: 917981
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Use of canrenoate potassium given orally in ascitogenic cirrhosis].
    Sarti F; Milandri GL; Piemontese A; Macchia S; Simoni S; Dal Monte PR
    Minerva Dietol Gastroenterol; 1984; 30(3):273-80. PubMed ID: 6504377
    [No Abstract]   [Full Text] [Related]  

  • 31. Severe electrolyte disorders following cardiac surgery: a prospective controlled observational study.
    Polderman KH; Girbes AR
    Crit Care; 2004 Dec; 8(6):R459-66. PubMed ID: 15566592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical study of potassium canrenoate on raised intracranial pressure.
    Node Y; Nakazawa S
    Adv Neurol; 1990; 52():557. PubMed ID: 2396562
    [No Abstract]   [Full Text] [Related]  

  • 33. Hypertonic-hyperoncotic solutions improve cardiac function in children after open-heart surgery.
    Schroth M; Plank C; Meissner U; Eberle KP; Weyand M; Cesnjevar R; Dötsch J; Rascher W
    Pediatrics; 2006 Jul; 118(1):e76-84. PubMed ID: 16751617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of spironolactone and K-canrenoate in ascitic cirrhosis. Double-blind study].
    Tempini S; Bellati G; Ideo G
    Minerva Dietol Gastroenterol; 1984; 30(3):255-61. PubMed ID: 6504374
    [No Abstract]   [Full Text] [Related]  

  • 35. [Study of the inotropic effect of potassium canrenoate by determining systolic time intervals].
    Vitolo E; Gambini E; Larovere MT; Rusconi F; Vitali GM
    Boll Soc Ital Cardiol; 1979; 24(7):775-7. PubMed ID: 554665
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of digitalis toxicity with intravenous potassium canrenoate.
    Gavrilescu G; Cristodorescu R; Deutsch G; Berger E
    Agressologie; 1977; 18(3):167-71. PubMed ID: 920909
    [No Abstract]   [Full Text] [Related]  

  • 37. [Plasma hyperosmolarity aspects in intensive care and its treatment with potassium canreonate].
    Ruggerini R; Mazzocchi F; Albini G; Cifalinò M
    Minerva Anestesiol; 1979 Sep; 45(9):687-90. PubMed ID: 117400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Aldosterone antagonists in coronary insufficiency].
    Osswald H
    Med Klin; 1978 Jan; 73(3):84-8. PubMed ID: 622061
    [No Abstract]   [Full Text] [Related]  

  • 39. Potassium canrenoate, an aldosterone receptor antagonist, reduces isoprenaline-induced cardiac fibrosis in the rat.
    Bos R; Mougenot N; Médiani O; Vanhoutte PM; Lechat P
    J Pharmacol Exp Ther; 2004 Jun; 309(3):1160-6. PubMed ID: 14764658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute anterior myocardial infarction.
    Di Pasquale P; Cannizzaro S; Scalzo S; Parrinello G; Fasullo S; Giambanco F; Fatta A; Paterna S
    Am Heart J; 2005 Nov; 150(5):919. PubMed ID: 16290961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.